Clinical trials: Neoadjuvant Treatment
Epithelial Ovarian Cancer
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
This study is to determine the feasibility of postoperative platinum-based chemotherapy plus adjuvant and maintenance bevacizumab after neoadjuvant chemotherapy followed by interval surgery in patients with extensive stage IIIC…
- Trial name
- NCT02022917
- Testing
- Bevacizumab
- Where
- 5 sites in Taiwan
- Volunteers
- 22 people
- Sponsor
- Chang Gung Memorial Hospital
Gastric Cancer (GC)
Prehabilitation Plus ERAS in Gastric Cancer Surgery
This study aims to evaluate the impact of pre-habilitation combined with Enhanced Recovery After Surgery (ERAS) versus ERAS perioperative management alone on clinical outcomes in patients with gastric cancer undergoing…
- Trial name
- NCT07328633
- Testing
- Pre-habilitation Program, Enhanced Recovery After Surgery (ERAS) Protocol
- Where
- China
- Volunteers
- 136 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Diabetes Mellitus, Type 1, Diabetic Nephropathy
European Trial of Immunosuppression in SPK Tx
1. To determine and compare the efficacy of Tacrolimus/Rapa versus Tacrolimus/MMF-based immunosuppression (in conjunction with initial short-term steroids and polyclonal antibody administration) in Type 1-diabetic patients…
- Trial name
- NCT00140543
- Testing
- sirolimus versus mycophenolate mofetil
- Where
- 14 sites in Austria, Belgium and 5 more
- Volunteers
- 228 people
- Sponsor
- EUROSPK Study Group
Breast Cancer
Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study
The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination…
- Trial name
- ASLAN (NCT04993625)
- Testing
- avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Jeong Eon Lee
Gastric Cancer
Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
To evaluate the safety of robot-assisted radical gastrectomy with D2 lymph node dissection in postoperative complications in patients with neoadjuvant chemotherapy for gastric cancer (cT3-4a, N+, M0).
- Trial name
- NCT05728606
- Testing
- Robot-assisted D2 distal gastrectomy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hebei Medical University
Fatigue, Breast Cancer
Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy
The goal of this clinical trial is to test the effect of the administration of APPORTAL® in addition to the SoC (recommended physical exercise), in patients with breast cancer, suffering from fatigue during neoadjuvant and…
- Trial name
- NCT06137833
- Testing
- APPOPRTAL®
- Where
- 5 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Pharmanutra S.p.a.
Sarcoma
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00023738
- Testing
- filgrastim, dacarbazine, doxorubicin hydrochloride
- Where
- 226 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous…
- Trial name
- NCT07133958
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhujiang Hospital
Leukemia
A Feasibility Study of Prophylactic White Blood Cell Transfusions
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk of infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and…
- Trial name
- NCT01932710
- Testing
- White Blood Cell Transfusion
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
TNBC - Triple-Negative Breast Cancer
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
Although many PARP inhibitors did not improve pCR in neoadjuvant studies, it is not an unchallenged conclusion that TNBC does not benefit from use of PARP inhibitors in neoadjuvant therapy.This study is an open-label, two-cohort…
- Trial name
- NCT05834582
- Testing
- Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Early-stage Breast Cancer
A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy
REaCT-5G will compare bone pain from a single dose of Pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy.
- Trial name
- NCT04781959
- Testing
- Filgrastim, Pegfilgrastim
- Where
- 2 sites in Canada
- Volunteers
- 233 people
- Sponsor
- Ottawa Hospital Research Institute
HR+/HER2- Breast Cancer, Breast Neoplasms
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
This study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in HR+/HER2…
- Trial name
- NCT07702708
- Testing
- Pre-treatment DCE-MRI-based AI model
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Fujian Cancer Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), Post Surgical
Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC
Patients with stage III non-small-cell lung cancer (NSCLC) who receive neoadjuvant chemoimmunotherapy may achieve good response in the primary tumor but still have residual nodal disease after surgery (ypTanyN⁺M0), which is…
- Trial name
- NCT07353476
- Testing
- radiotherapy, PD -1/PD-L1 monoclonal antibody
- Volunteers
- 38 people
- Sponsor
- Shanghai Zhongshan Hospital
Pathological Complete Remission, Objective Response Rate
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant…
- Conditions
- Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
- Trial name
- NCT07430579
- Testing
- adebrelimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The Second Hospital of Shandong University
NSCLC Non-small Cell Lung Cancer
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary…
- Trial name
- NCT02572843
- Testing
- MEDI4736 (anti-PD-L1)
- Where
- 19 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in treating patients with variant histology bladder cancer.
- Conditions
- Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma
- Trial name
- NCT03912818
- Testing
- Carboplatin, Cisplatin, Cystectomy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Colorectal Cancer
Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00427713
- Testing
- capecitabine, oxaliplatin, adjuvant therapy
- Where
- 72 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cancer Research UK
Head &Amp; Neck Squamous Cell Carcinoma
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)
This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.
- Trial name
- NeoTempo (NCT07147426)
- Testing
- Tislelizumab Combined With Chemotherapy for 4 cycles, Tislelizumab Combined With Chemotherapy for 2 cycles
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment.
- Trial name
- NCT04016389
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- 4 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.